BRAF Mutation Status in Primary, Recurrent, and Metastatic Malignant Melanoma and Its Relation to Histopathological Parameters
Background: BRAF mutations are a common finding in malignant melanoma (MM). Nevertheless, apart from their significance as a therapeutic target in advanced melanoma, their prognostic value is still debated. Objective: To assess BRAF mutation status in primary, recurrent, or metastatic MM and its co...
Guardado en:
Autores principales: | Aris Spathis, Alexander C Katoulis, Vasileia Damaskou, Aikaterini I. Liakou, Christine Kottaridi, Danai Leventakou, Dimitrios Sgouros, Andreas Mamantopoulos, Dimitrios Rigopoulos, Petros Karakitsos, Ioannis G. Panayiotides |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Mattioli1885
2019
|
Materias: | |
Acceso en línea: | https://doaj.org/article/8e09263f893b4a9ebb331dde7251d641 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Early Experience with Dabrafenib–Trametinib Combination in Patients with BRAF-Mutated Malignant Melanoma—A Single-Center Experience
por: Sandip Ganguly, et al.
Publicado: (2021) -
Dermoscopic Features as Predictors of BRAF Mutational Status and Sentinel Lymph Node Positivity in Primary Cutaneous Melanoma
por: Nika Filipović, et al.
Publicado: (2021) -
BRAF-Inhibitor-Induced Metabolic Alterations in A375 Melanoma Cells
por: Prashant Karki, et al.
Publicado: (2021) -
IGF1R/IR Mediates Resistance to BRAF and MEK Inhibitors in BRAF-Mutant Melanoma
por: Hima Patel, et al.
Publicado: (2021) -
Dermoscopy as a Tool in Differentiating Cutaneous Squamous Cell Carcinoma From Its Variants
por: Dimitrios Sgouros, et al.
Publicado: (2021)